Conferences - Results from #9480

Viewing 9481-9500 of 11487 articles

ASCO GU 2017: Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens - Session Highlights

ASCO GU 2017: Luminal and basal subtyping of prostate cancer. - Session Highlights

ASCO GU 2017: Advances in the Understanding and Treatment of Androgen-Receptor-Indifferent Prostate Cancer - Session Highlights

ASCO GU 2017: Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. - Session Highlights

ASCO GU 2017: The long tail of significantly mutated genes in prostate cancer - Session Highlights

ASCO GU 2017: Genomic Evolution in Primary and Therapy-Resistant Prostate Cancer - Session Highlights

ASCO GU 2017: Using Liquid Biopsies to Interrogate Circulating Tumor Clone Dynamics and Prostate - Session Highlights

ASCO GU 2017: Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci - Session Highlights

ASCO GU 2017: Active Surveillance Patient Perspective Question and Answer Panel - Session Highlights

ASCO GU 2017: Genomic Tests in Active Surveillance and the Role of Hereditary Testing - Session Highlights

ASCO GU 2017: Imaging To Guide Active Surveillance - Session Highlights

ASCO GU 2017: What ProtecT Tells Us About Active Surveillance - Session Highlights

ASCO GU 2017: Canadian Vs. U.S. Guidelines on Active Surveillance - Session Highlights

ASCO GU 2017: Welcome Address to the Genitourinary Cancer Symposium 2017 - Session Highlights

ASCO GU 2017: Some Patients Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early

ASCO GU 2017: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer

ASCO GU 2017: In Advanced Kidney Cancer, Antibiotic Use Lowers Efficacy of Immunotherapy

Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223.

Role of FSH in the musculoskeletal side effects associated with androgen deprivation therapy (ADT) for prostate cancer

470
471
472
473
474
475
476
477
478
479